| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
(±)-Taxifolin-13C3 does not have a specific biological target as a labeled compound. The unlabeled compound, (±)-Taxifolin, targets tyrosinase and collagenase. Tyrosinase is a copper-containing enzyme that catalyzes the first steps in melanin biosynthesis. Collagenase is an enzyme that breaks down collagen. Taxifolin inhibits both enzymes. The 13C3-labeled version is used as a tracer or internal standard and is not typically studied for its biological activity.
|
|---|---|
| ln Vitro |
In vitro, (±)-Taxifolin-13C3 is used as a research tool for metabolic studies and as an internal standard in mass spectrometry. The unlabeled compound, Taxifolin, exhibits important anti-tyrosinase activity and effectively inhibits collagenase with an IC50 of 193.3 μM. The 13C3-labeled version is not typically evaluated for these activities, as its primary use is analytical.
|
| ln Vivo |
In vivo activity is not applicable to (±)-Taxifolin-13C3, as it is an analytical standard.
|
| Enzyme Assay |
(±)-Taxifolin-13C3 is used in analytical protocols, particularly in LC-MS/MS methods for the quantification of Taxifolin. A standard protocol involves adding a known amount of the labeled internal standard to a biological sample, followed by extraction, chromatographic separation, and mass spectrometric detection.
|
| Cell Assay |
(±)-Taxifolin-13C3 is not used in cell-based assays for its biological effects.
|
| Animal Protocol |
(±)-Taxifolin-13C3 is not used in animal studies for therapeutic purposes. It is used as an analytical standard.
|
| ADME/Pharmacokinetics |
(±)-Taxifolin-13C3 is a stable isotope-labeled compound used as an analytical standard. It is not a drug.
|
| References |
|
| Additional Infomation |
(±)-Taxifolin-13C3 ((±)-Dihydroquercetin-13C3) is a research-grade stable isotope-labeled compound used as a derivative of (±)-Taxifolin for metabolic studies and as an internal standard. It has no therapeutic applications. The compound is available for research purposes.
|
| Molecular Formula |
C1213C3H12O7
|
|---|---|
| Molecular Weight |
307.23
|
| Appearance |
White to off-white solid powder
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
Typically soluble in DMSO (e.g. 10 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.2549 mL | 16.2745 mL | 32.5489 mL | |
| 5 mM | 0.6510 mL | 3.2549 mL | 6.5098 mL | |
| 10 mM | 0.3255 mL | 1.6274 mL | 3.2549 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
